Thus, it remains unclear whether insulin therapy worsens COVID-19 outcomes or if these results were caused by a patient selection bias (note: patients with diabetes receiving insulin tend to have longer duration of disease with a higher rate of comorbidities). Here, INS is linked to COVID-19.